These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28592202)

  • 1. Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients.
    Sini V; Botticelli A; Lunardi G; Gori S; Marchetti P
    Pharmacogenomics; 2017 Jun; 18(8):821-830. PubMed ID: 28592202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis.
    Artigalás O; Vanni T; Hutz MH; Ashton-Prolla P; Schwartz IV
    BMC Med; 2015 Jun; 13():139. PubMed ID: 26067721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics of third-generation aromatase inhibitors.
    Turkistani A; Marsh S
    Expert Opin Pharmacother; 2012 Jun; 13(9):1299-307. PubMed ID: 22594760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline variants in the CYP19A1 gene are related to specific adverse events in aromatase inhibitor users: a substudy of Dutch patients in the TEAM trial.
    Fontein DB; Houtsma D; Nortier JW; Baak-Pablo RF; Kranenbarg EM; van der Straaten TR; Putter H; Seynaeve C; Gelderblom H; van de Velde CJ; Guchelaar HJ
    Breast Cancer Res Treat; 2014 Apr; 144(3):599-606. PubMed ID: 24590773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP19A1 rs10046 Pharmacogenetics in Postmenopausal Breast Cancer Patients Treated with Aromatase Inhibitors: One-year Follow-up.
    Baatjes K; Peeters A; McCaul M; Conradie MM; Apffelstaedt J; Conradie M; Kotze MJ
    Curr Pharm Des; 2020; 26(46):6007-6012. PubMed ID: 32900345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP11A1 expression in bone is associated with aromatase inhibitor-related bone loss.
    Rodríguez-Sanz M; García-Giralt N; Prieto-Alhambra D; Servitja S; Balcells S; Pecorelli R; Díez-Pérez A; Grinberg D; Tusquets I; Nogués X
    J Mol Endocrinol; 2015 Aug; 55(1):69-79. PubMed ID: 26108486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Personalizing aromatase inhibitor therapy in patients with breast cancer.
    Hamadeh IS; Patel JN; Rusin S; Tan AR
    Cancer Treat Rev; 2018 Nov; 70():47-55. PubMed ID: 30086432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attempted replication of SNPs in RANKL and OPG with musculoskeletal adverse events during aromatase inhibitor treatment for breast cancer.
    Dempsey JM; Xi J; Henry NL; Rae JM; Hertz DL
    Physiol Genomics; 2018 Feb; 50(2):98-99. PubMed ID: 29212847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy.
    Santa-Maria CA; Blackford A; Nguyen AT; Skaar TC; Philips S; Oesterreich S; Rae JM; Desta Z; Robarge J; Henry NL; Storniolo AM; Hayes DF; Blumenthal RS; Ouyang P; Post WS; Flockhart DA; Stearns V;
    Clin Cancer Res; 2016 Mar; 22(6):1395-402. PubMed ID: 26463708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP1A2--a novel genetic marker for early aromatase inhibitor response in the treatment of breast cancer patients.
    Simonsson M; Veerla S; Markkula A; Rose C; Ingvar C; Jernström H
    BMC Cancer; 2016 Mar; 16():256. PubMed ID: 27029552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.
    Napoli N; Rastelli A; Ma C; Colleluori G; Vattikuti S; Armamento-Villareal R
    Pharmacogenet Genomics; 2015 Aug; 25(8):377-81. PubMed ID: 26049585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of aromatase inhibitors.
    Hadfield KD; Newman WG
    Pharmacogenomics; 2012 Apr; 13(6):699-707. PubMed ID: 22515612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.
    Liu X; Low SK; Boddy AV
    Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):851-63. PubMed ID: 27253864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients.
    Lintermans A; Van Asten K; Jongen L; Van Brussel T; Laenen A; Verhaeghe J; Vanderschueren D; Lambrechts D; Neven P
    Eur J Cancer; 2016 Mar; 56():31-36. PubMed ID: 26798969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study.
    Garcia-Giralt N; Rodríguez-Sanz M; Prieto-Alhambra D; Servitja S; Torres-Del Pliego E; Balcells S; Albanell J; Grinberg D; Diez-Perez A; Tusquets I; Nogués X
    Breast Cancer Res Treat; 2013 Jul; 140(2):385-95. PubMed ID: 23868189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Research on aromatase gene (CYP19A1) polymorphisms as a predictor of endocrine therapy effectiveness in breast cancer.
    Miron L; Negură L; Peptanariu D; Marinca M
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):997-1004. PubMed ID: 23700878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic Underpinnings of Musculoskeletal Pain During Treatment With Aromatase Inhibitors for Breast Cancer: A Biological Pathway Analysis.
    Zhu Y; Koleck TA; Bender CM; Conley YP
    Biol Res Nurs; 2020 Apr; 22(2):263-276. PubMed ID: 31847542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New pharmacogenomic paradigm in breast cancer treatment.
    Offit K; Robson ME
    J Clin Oncol; 2010 Nov; 28(31):4665-6. PubMed ID: 20876427
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacogenomics of tamoxifen and aromatase inhibitors.
    Ingle JN
    Cancer; 2008 Feb; 112(3 Suppl):695-699. PubMed ID: 18072234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of Geriatric screening tool (G8) in predicting side effect in older patients during therapy with aromatase inhibitor.
    Dottorini L; Catena L; Sarno I; Di Menna G; Marte A; Novelli E; Rusca C; Bajetta E
    J Geriatr Oncol; 2019 Mar; 10(2):356-358. PubMed ID: 30333087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.